Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Waxman

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1986
The first clinical use of depot buserelin for advanced prostatic carcinomaJ H Waxman, J Sandow, A Man, et al.
Haematology and Blood Transfusion|January 1, 1985
The feasibility of opal/high dose Ara-C treatment of adult acute lymphoblastic leukaemiaM J Barnett, A Z Rohatiner, M A Richards, et al.
British Journal of Urology|December 1, 1983
Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormoneJ H Waxman, J A Wass, W F Hendry, et al.
Diabetes Care|June 1, 1997
IDDM incidence in a multiracial population. The Hawaii IDDM Registry, 1980-1990S L Patrick, J K Kadohiro, S H Waxman, et al.
British Journal of Cancer|June 1, 1989
Kinetics, quantitative analysis and radioimmunolocalization using indium-111-HMFG1 monoclonal antibody in patients with breast cancerH P Kalofonos, J M Sackier, M Hatzistylianou, et al.
Annals of Internal Medicine|July 15, 1994
The in-training examination in internal medicineR A Garibaldi, M C Trontell, H Waxman, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1987
Failure to preserve fertility in patients with Hodgkin's diseaseJ H Waxman, R Ahmed, D Smith, et al.
Progress in Experimental Tumor Research|January 1, 1985
Neurotoxicity of high-dose cytosine arabinosideM J Barnett, T S Ganesan, J H Waxman, et al.
Seminars in Oncology|June 1, 1985
Central nervous system toxicity of high-dose cytosine arabinosideM J Barnett, M A Richards, T S Ganesan, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1988
Chemical synthesis and enzymatic activity of a 99-residue peptide with a sequence proposed for the human immunodeficiency virus proteaseR F Nutt, S F Brady, P L Darke, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Cancer Chemotherapy and Pharmacology|January 1, 1986
The first clinical use of depot buserelin for advanced prostatic carcinomaJ H Waxman, J Sandow, A Man, et al.
Haematology and Blood Transfusion|January 1, 1985
The feasibility of opal/high dose Ara-C treatment of adult acute lymphoblastic leukaemiaM J Barnett, A Z Rohatiner, M A Richards, et al.
British Journal of Urology|December 1, 1983
Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormoneJ H Waxman, J A Wass, W F Hendry, et al.
Diabetes Care|June 1, 1997
IDDM incidence in a multiracial population. The Hawaii IDDM Registry, 1980-1990S L Patrick, J K Kadohiro, S H Waxman, et al.
British Journal of Cancer|June 1, 1989
Kinetics, quantitative analysis and radioimmunolocalization using indium-111-HMFG1 monoclonal antibody in patients with breast cancerH P Kalofonos, J M Sackier, M Hatzistylianou, et al.
Annals of Internal Medicine|July 15, 1994
The in-training examination in internal medicineR A Garibaldi, M C Trontell, H Waxman, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1987
Failure to preserve fertility in patients with Hodgkin's diseaseJ H Waxman, R Ahmed, D Smith, et al.
Progress in Experimental Tumor Research|January 1, 1985
Neurotoxicity of high-dose cytosine arabinosideM J Barnett, T S Ganesan, J H Waxman, et al.
Seminars in Oncology|June 1, 1985
Central nervous system toxicity of high-dose cytosine arabinosideM J Barnett, M A Richards, T S Ganesan, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1988
Chemical synthesis and enzymatic activity of a 99-residue peptide with a sequence proposed for the human immunodeficiency virus proteaseR F Nutt, S F Brady, P L Darke, et al.
Pageof 6